Barcelona, Spain (UroToday.com) Following the presentation of PROfound, Dr. Eleni Efstathiou provided an invited discussion of this study. Dr. Efstathiou notes that this is the first targeted therapy Phase III prostate cancer trial to deliver positive results. Patients with germline BRCA mutation carriers have a poor prognosis and do not respond well to cytotoxic therapies, thus there is an unmet need in this population. However, Dr. Eleni asks whether we should extrapolate from the germline BRCA landscape to somatic BRCA? The answer is yes, as germline and somatic mutations are equally common, and biallelic loss occurs at the same time at the same high frequency in prostate cancer.
Non-Accredited
Barcelona, Spain (UroToday.com) Despite significant progress in systematic therapy, metastatic castration-resistant prostate cancer (mCRPC) continues to be a lethal disease. mCRPC is molecularly heterogeneous, as up to 30% of mCRPC harbor deleterious alterations in DNA damage repair genes, including those with direct and indirect roles in homologous recombination repair. These loss-of-function alterations in homologous recombination repair genes are associated with response to PARP inhibition, of which BRCA1, BRCA2, and ATM are the most well characterized.
Non-Accredited